|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 100 DAINGERFIELD ROAD |
Address2 | 3rd FLOOR |
City | ALEXANDRIA |
State | VA |
Zip Code | 22314 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 27478-12
|
||||||||
|
6. House ID# 303540000
|
TYPE OF REPORT | 8. Year | 2017 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Karry La Violette |
Date | 10/20/2017 2:07:53 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
Implementation of Public Law 114-198 pharmacy provisions;
Implementation of Public Law 114-255 pharmacy provisions;
H.R. 1854/S. 778, Prescription Drug Monitoring Act of 2017;
S 892, Opioid Addiction Prevention Act of 2017;
HR 3528, Every Prescription Conveyed Securely Act;
H.R. 3545, Overdose Prevention and Patient Safety Act;
S. 1850, Protecting Jessica Grubbs Legacy Act;
H.R. 1271, DXM Abuse Prevention Act of 2017;
H.R. 1375, Prescriber Support Act of 2017;
S. 523, Budgeting for Opioid Addiction Treatment Act;
S. 581, Jessies Law;
S 1079, Protecting Americans from Dangerous Opioids Act;
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
La Violette |
|
|
|
Susan |
Pilch |
|
|
|
Michael |
Tomberlin |
|
|
|
Ronna |
Hauser |
|
|
|
Kevin |
Schweers |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Issues related to compounded pharmaceuticals for animals;
H.R. 623, FairnesstoPetOwnersActof 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
La Violette |
|
|
|
Susan |
Pilch |
|
|
|
Michael |
Tomberlin |
|
|
|
Ronna |
Hauser |
|
|
|
Kevin |
Schweers |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act;
H.amdt. 278, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, specifically FDA funding for implementation of the Drug Quality and Security Act.;
H.R. 1628, American Health Care Act of 2017;
Better Care Reconciliation Act;
H.R. 2430 the FDA Reauthorization Act (FDARA) of 2017;
S.934 FDA Reauthorization Act of 2017;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Agriculture - Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), White House Office, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
La Violette |
|
|
|
Susan |
Pilch |
|
|
|
Michael |
Tomberlin |
|
|
|
Ronna |
Hauser |
|
|
|
Kevin |
Schweers |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
Supporting implementation of Sec. 745 of National Defense Authorization Act for Fiscal Year 2017;
H.R. 2810 - National Defense Authorization Act for Fiscal Year 2018-
Generic drug pricing transparency and TRICARE Pharmacy Benefits Provisions;
S. 1519 National Defense Authorization Act for Fiscal Year 2018- Generic drug pricing transparency and TRICARE Pharmacy Benefits Provisions
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Defense - Dept of (DOD)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
La Violette |
|
|
|
Susan |
Pilch |
|
|
|
Michael |
Tomberlin |
|
|
|
Ronna |
Hauser |
|
|
|
Kevin |
Schweers |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S. 222, The Obama Care Replacement Act;
S. 469, Affordable and Safe Prescription Drug Importation Act;
H.R. 1245, Affordable and Safe Prescription Drug Importation Act;
H.R. 1776, Improving Access to Affordable Prescription Drugs Act;
S. 771, Improving Access to Affordable Prescription Drugs Act;
H.R. 242, Medicare Prescription Drug Price Negotiation Act of 2017;
S. 41, Medicare Prescription Drug Price Negotiation Act of 2017;
Drug Pricing Transparency
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), White House Office, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
La Violette |
|
|
|
Susan |
Pilch |
|
|
|
Michael |
Tomberlin |
|
|
|
Ronna |
Hauser |
|
|
|
Kevin |
Schweers |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 1316, Prescription Drug Price Transparency Act;
H.R. 1038, Improving Transparency and Accuracy in Medicare Part D Spending Act;
S. 413, Improving Transparency and Accuracy in Medicare Part D Spending Act;
H.R. 592, Pharmacy and Medically Underserved Areas Enhancement Act;
S. 109, Pharmacy and Medically Underserved Areas Enhancement Act;
H.R.1939 - To amend title XVIII of the Social Security Act to ensure equal access of Medicare beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage, and for other purposes;
S.637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017;
HR 394/ S 85, Restoring Access to Medication Act;
HR 3921/S 1827, KIDS Act of 2017;
HR 3271, Protecting Access to Diabetes Supplies Act of 2017;
S. 870, Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Discussion draft, preventing cash price disclosure restrictions under Medicare prescription drug plan contracts with pharmacies
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Personnel Management (OPM), Office of Management & Budget (OMB), Government Accountability Office (GAO), Medicare Payment Advisory Commission (MedPAC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
La Violette |
|
|
|
Susan |
Pilch |
|
|
|
Michael |
Tomberlin |
|
|
|
Ronna |
Hauser |
|
|
|
Kevin |
Schweers |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Congressional Oversight of 340 B Program;
Issues related to FDA implementation of The Drug Quality and Security Act related to the regulations of pharmacy compounding;
Biosimilar naming;
H.R. 421 Allowing Greater Access to Safe and Effective Contraception Act;
H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017;
HR 749, Lower Drug Costs through Competition Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Personnel Management (OPM), Government Accountability Office (GAO), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
La Violette |
|
|
|
Susan |
Pilch |
|
|
|
Michael |
Tomberlin |
|
|
|
Ronna |
Hauser |
|
|
|
Kevin |
Schweers |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Unified Framework for Fixing Our Broken Tax Code;
H.R. 631, Death Tax Repeal Act of 2017;
S. 205, Death Tax Repeal Act of 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Natl Economic Council (NEC), Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
La Violette |
|
|
|
Susan |
Pilch |
|
|
|
Michael |
Tomberlin |
|
|
|
Ronna |
Hauser |
|
|
|
Kevin |
Schweers |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |